Replimune Group, Inc. Cash and Equivalents

Quick Answer

Replimune Group, Inc. reported Cash and Equivalents of $111.12 million for fiscal year 2025.

Replimune Group, Inc. Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2025 $111.12M +49.2%
2024 $74.46M -49.2%
2023 $146.59M +38.4%
2022 $105.95M -42.0%
2021 $182.52M +206.8%
2020 $59.50M +131.5%
2019 $25.70M +46.2%
2018 $17.58M

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
December 31, 2025 $122.95M -28.6% +20.2%
September 30, 2025 $102.30M -9.9% +5.1%
June 30, 2025 $97.37M -35.8% -12.4%
March 31, 2025 $111.12M +49.2% -35.5%
December 31, 2024 $172.25M +76.4% +51.8%
September 30, 2024 $113.49M +49.3% -25.2%
June 30, 2024 $151.66M +42.4% +103.7%
March 31, 2024 $74.46M -49.2% -23.8%
  • Replimune Group, Inc. showed an increase of +49.2% in Cash and Equivalents compared to the prior fiscal year.
  • Over the 2018–2025 period, Replimune Group, Inc.’s cash and equivalents has grown by 532.0% (from $17.58 million to $111.12 million).
  • The most recent figure is from Replimune Group, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 22, 2025.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment